Trial · NCT05792761
A Study on Antiviral Treatment of Chronic Hepatitis B in Children
NCT05792761, Not applicable, Unknown, Fang Wang
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study on Antiviral Treatment of Chronic Hepatitis B in Children. Trials, record NCT05792761. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05792761
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study on Antiviral Treatment of Chronic Hepatitis B in Children
- NCT number
- NCT05792761
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 1,900 participants, estimated
- Lead sponsor
- Fang Wang
- Conditions
- Chronic HBV Infection
- Interventions
- Peginterferon alfa-2b combined and ETV
- First posted
- 2023-03-31
- Last updated
- 2023-03-31
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical cure rate. | 24 weeks after completing treatment. | Defined as the proportion of child patients with HBsAg \< 0.05 IU / mL (or below the lower detection limit) 24 weeks after completing treatment, HBeAg negative, HBV DNA undetectable, and normalization of liver biochemical indexes (ALT and AST). |
| Secondary | Proportion of patients with HBV-DNA negative in those with HBV-DNA positive at baseline. | 24 weeks after treatment completion | Defined as HBV-DNA below the lower detection limit, or\< 20 IU/mL. |
| Secondary | HBeAg seroconversion rate in HBeAg positive children. | 24 weeks after treatment completion. | Defined as HBeAg negative and anti-HBe positive. |
| Secondary | HBsAg seroconversion rate. | 24 weeks after treatment completion. | Defined as HBsAg \< 0.05 IU/mL and anti-HBe positive. |
| Secondary | ALT normalization rate. | 48 weeks and 96 weeks after starting treatment | |
| Secondary | Decrease of HBV-DNA compared to baseline. | 24 weeks after treatment completion. | |
| Secondary | Decrease of HBeAg compared to baseline. | 24 weeks after treatment completion. | |
| Secondary | Decrease of HBsAg compared to baseline. | 24 weeks after treatment completion. | |
| Secondary | The incidence of adverse reactions. | 24weeks ,48 weeks and 96 weeks after starting treatment | Including fever, influenza-like symptoms, decreased hemogram, jaundice ALT\> 400U/L, abnormal renal function, abnormal thyroid function, abnormal blood phosphorus and blood calcium during treatment (lower or higher than the normal value). |
| Secondary | The effects on height | 24weeks ,48 weeks and 96 weeks after starting treatment |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05792761
GET https://conductscience.org/api/trials/v1/NCT05792761/registered